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ABSTRACT In the coronavirus disease 2019 (COVID-19) pandemic year 2020, the 30th European
Respiratory Society (ERS) International Congress took place for the first time in a fully virtual format.
Despite the challenging nature of the task to create and deliver an online event of this size and scope, it
turned out to be a great success, welcoming over 33000 delegates to the specially designed online platform
and offering more than 450 scientific and educational sessions. Somewhat predictably, this year’s ERS
International Congress dedicated a full day to the topic of COVID-19, highlighting that infection with
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease that is particularly
important this year. In this article, the Early Career Members of the Assembly 10 (Respiratory Infections
and Tuberculosis) review some of the most interesting sessions including presentations and posters on
respiratory infections and tuberculosis that were deemed as important.
@ERSpublications
This is a comprehensive summary of several interesting sessions from #ERSCongress 2020
including presentations and posters on respiratory infections and tuberculosis that were deemed
as important https://bit.ly/2OtrYXH
Cite this article as: Frent S, Calarasu C, Suska K, et al. ERS International Congress 2020: highlights
from the Respiratory Infections assembly. ERJ Open Res 2021; 7: 00091-2021 [https://doi.org/
10.1183/23120541.00091-2021].
Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-
Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Received: 4 Feb 2021 | Accepted after revision: 25 Feb 2021




T. Welte opened the ERS Virtual Congress 2020 with a keynote lecture entitled “COVID-19:
recapitulation”. At the time of this presentation, there were 27 million SARS-CoV-2 infections and 875000
deaths recorded worldwide. This is a novel virus, and T. Welte stressed the challenges of day-to-day
changes in knowledge in terms of diagnosis, treatment and preventative measures. In early September,
patient numbers were beginning to decrease in many countries and the case fatality rate was reducing
from 10–15% to 3–5% worldwide [1].
T. Welte gave an overview of the COVID-19 pandemic, with the first case of COVID-19 being reported in
Wuhan, China, on the December 8, 2019. Infection spread through the city of Wuhan, causing the
healthcare system to be overwhelmed and subsequently a large increase in mortality. This was followed by
cases being detected in the larger Hubei region; however, as the healthcare system remained intact
mortality was 10-times lower than during the initial Wuhan outbreak. A strict lockdown policy was
imposed, which rapidly brought down the infection rate, with preventative messages still on a high level
and virus transmission low as of September 2020 [2, 3].
The virus arrived in Europe in January 2020, believed to have been exacerbated by Italian Fashion Week
due to increased travel by international visitors. Several “superspreader” events, such as a football game in
Milan on February 21, contributed to the spread of the virus in Europe. A breakdown in healthcare
systems in a number of countries, including Italy, Spain, France and the UK led to an increase in daily
mortality caused, in part, by COVID-19 but also from a lack of normal healthcare services for other
conditions [4]. The delayed arrival of the pandemic in Germany resulted in an improved response to the
outbreak. Unlike a number of other European countries, Germany saw no increase in daily mortality
during the first wave of the pandemic. T. Welte emphasised that the instigation of an earlier lockdown, a
more robust healthcare system, differences in living conditions and an improved knowledge of appropriate
treatments were key factors in improving the response to the pandemic.
T. Welte’s conclusions underlined the importance of scientific and clinical advice in combating the
pandemic, while emphasising that strategies and decisions must be adaptable in this rapidly evolving
situation.
New developments in pandemic medicine: an update from the PREARE research
project
The aim of this session was to describe the latest developments in antiviral therapy for influenza and the
growing problem of arbovirus infection in Europe, to evaluate the rationale for adaptive trials investigating
critical care interventions in a pandemic, and to describe a collaborative strategy for increasing clinical and
research capacity in Europe for pandemic care.
C. Butler reviewed the latest results for the Antivirals for influenza-Like Illness? An rCt of Clinical and
Cost-effectiveness in primary CarE (ALIC4E) of oseltamivir, an antiviral therapy for influenza. A Cochrane
collaboration review [5] which summarised the previous ROCHE funded trials of oseltamivir found that
treatment alleviated symptoms in adults at 16.8 h compared with placebo. However, the review also
contained criticism of trial design, including a lack of diagnostic definitions for complications of
influenzae and low numbers of paediatric patients and patients with co-morbidities. A BMJ editorial [6]
concluded that a large definitive clinical trial that focussed on understudied groups by an independent
body was required to assess whether adding oseltamivir treatment in primary care was truly worthwhile.
ALIC4E [7] was designed to meet these criteria. The trial encompassed 21 networks over 15 countries in
207 primary care practices. 3259 patients were randomised, 14% of whom were children aged under
12 years. 15% of subjects had a chronic comorbidity, and an increase in distribution of illness severity and
a range of time that subjects could be symptomatic for compared to previous trials. Trial results found that
time to recovery was shorter in participants receiving oseltamivir (hazard ratio 1.29, 95% Bayesian credible
interval (BCrI) 1.20–1.39) overall. The estimated absolute mean benefit from oseltamivir was 1.02 days
(95% BCrI 0.74–1.31) overall, and ranged from 0·70 (95% BCrI 0.30–1.20) in patients younger than
12 years, with less severe symptoms, no comorbidities, and shorter previous illness duration to 3.20 (95%
BCrI 1.00–5.50) in patients aged ⩾65 years who had more severe illness, comorbidities and longer
previous illness duration. To conclude, although the average benefit for many patients is modest, older
patients who are more severely unwell may have an improvement in recovery time of 2–3 days.
L. Sigfrid discussed the work of ISARIC (International Severe Acute Respiratory and emerging Infection
Consortium) [8]. ISARIC is a global federation of clinical research member networks involved in
patient-based research, with a mission to prevent illness and deaths from infectious disease outbreaks. The
consortium aims to enable timely, robust, standardised patient-based research as the heart of an
evidence-based response to epidemics and pandemics. Made up of 50 networks in 132 countries, these
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pre-existing networks are a key enabler for rapid standardised response. ISARIC has previously responded
to other pandemics in collaboration with the World Health Organization (WHO). Together, they have
developed a Clinical Characterisation Protocol (CCP), designed to respond to any emerging pathogen that
is of public health interest. CCP is designed to have a flexible tiered approach, which is adaptable
depending on site resources in order to standardise patient data. Tier 0 is for data collection only, tier 1
for data collection and admission samples and tiers 2–3 are for data collection and serial sampling
depending on resources. Associated with the protocol is a range of collection tools which standardise data
collection. CCP protocols have been activated in response to other emerging pathogens, including Middle
East respiratory syndrome coronavirus (2012), influenza H7N9 (2013), ebolavirus (2014), monkeypox
(2018), tick-borne encephalitis virus (2019) and was initiated in January 2020 in response to COVID-19.
In January 2020, data from China on the COVID-19 outbreak was reviewed and an updated core
COVID-19 case report form launched, later followed by a RAPID COVID-19 case report form which
included additional modules for sites able to collect more complex data in critical care. Protocols are open
access: sites are able to sign up to capture electronic data in a standardised format. By August 25, more
than 96000 patient data records were on the database, across 562 sites and 42 countries.
L. Sigfrid gave an overview of the emerging data; 81705 (82%) individual had laboratory-confirmed
SARS-CoV-2 (as of August 6, 2020). 57% were male with a median age of 71 years. The most common
symptoms recorded were cough (62%), fever (61%), shortness of breath (59%) and fatigue/malaise (36%).
Other common symptoms included altered consciousness, nausea/vomiting and diarrhoea. The most
common comorbidities were hypertension (46%), chronic cardiac disease (30%), chronic kidney disease
(16%) and diabetes (16%), and 14.5% of subjects had no recorded co-morbidities. Median onset of
symptoms after admission was 4 days, with the median length of hospital stay being 9 days. Of patients
with an outcome recorded, 58% recovered, 28% of patients died (62% male, 38% female) and this rose to
34% in patients admitted to ICU. In terms of treatment, 81% of patients received antibiotics, 65% received
oxygen therapy and 17% received steroids. A subset analysis was done in the UK cohort assessing the
impact of COVID-19 paediatric admissions. The analysis included 651 children, with a median age of
4.6 years, with 42% having one or more comorbidities. The death rate was very low at 1%, with all patients
having profound comorbidities [9]. To conclude, L. Sigfrid presented the launch of the ISARIC follow up
studies, with an invitation for other sites to join the consortium.
G. Carson, in her review entitled “What’s next – preparing for the ongoing COVID response and future
pandemics”, explored what the pandemic has taught us so far. The COVID-19 pandemic put healthcare
workers in a unique position, of responding, recovering and preparing for resurgences
simultaneously. G. Carson discussed the work of the Global Preparedness Monitoring Board (GPMB),
which was created in 2018 after the ebola outbreak shed light on the major gaps in political, research
public health systems” capacity to prevent, detect and respond to health crises from local to global levels.
A report by HERTEN-CRABB et al. [10] examined 26 recommendations for dealing with global health
emergencies, focussing on global coordination and governance. A key finding of the report was the
“Global Safety Net” which highlighted the importance of strengthening global preparedness and response.
COVID-19 has had immense social, health and economic costs and the pandemic has demonstrated the
need for a collective global response. Social determinants of health play a role in the increased risk faced
by certain groups. Effective response to outbreaks should consider multiple disciplines, including health
care, research, social impact and political policy. To conclude, G. Carson highlighted WHO “Sustainable
Development Goals (SDGs)” as a pathway to improving global cohesion and response, as well as the
importance of working with communities, avoiding politisation, implementing a systems-based approach
across sectors, securing funding for public health and scenario planning to tackle COVID-19 globally.
Post-COVID session
The long-term effects of COVID-19 are relatively unknown; researchers are exploring parallels with other
disease and trialling long-term management options. The aim of this session was to discuss the current
care pathways, rehabilitation options, long-term impact on the lung and palliative care for patients.
I. Vogiatzis started the session by highlighting the effects of COVID-19 on physical, functional and
emotional health. It has been well documented that patients with COVID-19 report physical functional
disability during hospital admission and after discharge. Pulmonary function is also reduced at admission
but typically improves after 6 weeks, although some degree of restrictive alterations still persists [11]. In
addition to physical symptoms, there is a substantial prevalence of anxiety and depression among patients
with COVID-19 [12]. ERS has issued guidance on the hospital and post-hospital phases of COVID-19 [13],
which has been compiled by 93 experts from 23 countries. The proposed care pathway covers guidance
from bedside rehabilitation in the hospital setting through to discharge and follow-up. The guidance
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recommends formal assessment at 6–8 weeks of: physical and emotional function, patient core outcomes,
respiratory function, exercise capacity and need for rehabilitation. Based on the outcomes of this
assessment, patients should be offered support to aid their recovery, including comprehensive
rehabilitation, muscle strengthening programmes, nutritional guidance and psychological support.
The British Thoracic Society (BTS) has also issued guidance on rehabilitation to support recovery of the
post-COVID population [14]. The BTS care pathway recommends that, within 6–8 weeks, patients should
be referred to pulmonary rehabilitation team for assessment and subsequent follow up. I. Vogiatzis
highlighted that with physical distancing rules in many places due to the pandemic, there is a need for
some rehabilitation and assessment to happen remotely. Virtual consultations can be utilised to assess a
range of core outcomes to facilitate the implementation of recovery programs. Virtual sessions should aim
to give patients a programme to follow at home, including psychological support, nutritional guidance,
advice on physical activity and diaries to track symptoms and recovery. In response to COVID-19,
healthcare professional consultations should be employed to assess key outcomes and provide recovery
programmes for patients.
S. Singh summarised the impact of COVID-19 on patients, which treatable traits are involved and how
rehabilitation pathways may aid recovery. A study of 143 patients in an Italian cohort found that patients
who had recovered from COVID-19 continued to report persistence of at least one symptom, in particular
fatigue, breathlessness, joint pain and chest pain [15]. Additionally, patients have reported a profound
reduction in exercise capacity post-COVID, even in younger patient populations. In terms of psychological
health, post-traumatic stress disorder, anxiety and depression have all been reported by patients. Current
rehabilitation programmes should be updated to reflect the new post-COVID population and the specific
challenges they present. Programmes should consider including psychological and fatigue support, speech
and language therapy for patients who have been ventilated and nutritional support as well as pulmonary
rehabilitation.
F. Blasi discussed the long-term impact of COVID-19 on the lungs. Post-discharge, patients have reported
symptoms, such as breathlessness, fatigue, anxiety and depression, and as many as one in two patients
have symptoms at follow-up [15]. There is growing evidence that SARS-CoV-2 infection can lead to
pulmonary fibrosis [16]. In a study of 110 post-COVID patients, more than one-third of patients
discharged developed fibrotic abnormalities, 47% had impaired diffusing capacity of the lungs for carbon
monoxide and 25% had reduced total lung capacity [17]. It has been speculated that acute and chronic
inflammation in COVID-19 results in alveolar epithelium damage, which stimulates over expression of
pro-inflammatory cytokines. This leads to fibroblasts and myofibroblast activation, followed by excessive
deposition of collagen in the extracellular matrix resulting in pulmonary fibrosis. There is currently little
evidence for which therapies are most appropriate to treat these patients, although potential treatments
include steroids, current idiopathic pulmonary fibrosis (IPF) treatments and anti-viral medications. Finally,
F. Blasi highlighted that COVID-19 infection is associated with ongoing myocardial inflammation,
independent of pre-existing conditions, severity and overall course of acute illness.
D. Janssen led the final session discussing palliative care for COVID-19 patients. There are specific
challenges to COVID-19 palliative care: patient deterioration can be fast and unpredictable, healthcare
systems are under immense burden due to the pandemic, patients require isolation, family visits are
restricted or carried out remotely and communication is hampered by personal protective equipment
(PPE). In a study of 101 patients receiving palliative care for COVID-19, the reported symptom burden
was predominately breathlessness (66%), agitation (43%), drowsiness (35%), delirium (24%) and pain
(23%) [18]. In order to guide healthcare professionals (HCP) and improve palliative care for patients an
ERS taskforce was formed. 90 international experts completed an online survey on 14 potential
recommendations, with at least 70% agreement on directionality required for consensus recommendations.
Recommendations have been provided for 14 domains including: advance care planning, palliative
treatment of breathlessness, need for training in optimising patient–clinician communication while
wearing PPE, training for remote clinician-family communication, involvement in HCPs trained in
palliative care, involvement of HCPs providing spiritual and psycho-social care, bereavement support for
patients and support for HCPs. This multi-national consensus can be accessed through the European
Respiratory Journal [19].
The future of bronchiectasis management
The aims of this session were to describe the effects of early life, including demographic, inflammatory
and genetic factors, on the development of bronchiectasis; to review recent randomised studies and
observational data that are leading to improvements in the management of bronchiectasis; to describe
current options for the management of Pseudomonas aeruginosa pulmonary infections in patients with
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bronchiectasis; and to describe possible future treatments for bronchiectasis in adults. The session was
chaired by G.G.U. Rohde (Frankfurt, Germany) and E. Polverino (Barcelona, Spain).
K. Ramsey (Bern, Switzerland) opened the session by highlighting the role of altered airway mucus viscosity
in the pathogenesis of bronchiectasis [20] and the relatively low number of studies characterising mucus
composition in bronchiectasis patients [21]. Recently published results of an experiment conducted by RAMSEY
et al. [22] at the University of North Carolina at Chapel Hill, USA, on the airway mucus concentration in
patients with non-cystic fibrosis bronchiectasis were further presented. The aim of the study was to assess
concentration, composition and biophysical properties of bronchiectasis mucus in sputum samples collected
from subjects enrolled in the BLESS trial [23] compared with mucus obtained from healthy control subjects.
K. Ramsey and colleagues found a hyperconcentration of mucus in bronchiectasis patients compared to
healthy subjects, with MUC5B and MUC5AC being the major secreted mucins. Mucus hyperconcentration
and altered biophysical properties (increased osmotic pressure and increased complex viscosity) are further
responsible for impaired mucociliary and cough clearance. The researchers also found a positive
correlation between mucus concentration and bronchiectasis extent score, but no correlation with forced
expiratory volume in 1 s, and the neutrophilic inflammation being driven by high bacterial loads of all
pathogens, not just Pseudomonas spp. Previous studies have demonstrated neutrophil elastase to be a key
driver of the disease [24–26] by inducing persistent muco-obstruction and triggering interleukin
(IL)-1β-driven inflammatory cascade, leading ultimately to the development of bronchiectasis [27].
Hypertonic saline reduced mucin concentration by 25% in induced sputum samples [22]; however, clinical
trials assessing effectiveness of mannitol and hypertonic saline in patients with bronchiectasis showed
mixed results. Both mucoactive drugs demonstrated an improvement in the quality of life, but no
significant effect on the number of exacerbations [28].
Ramsey concluded the presentation by proposing a reliable and relatively easy to use biomarkers for
identification of patients who would benefit from muco-modulatory treatment: sputum dry to wet weight ratio.
A. O’Donnell from Georgetown University (WA, USA) gave a perspective on the current state-of-the-art
management of bronchiectasis. While the cure of bronchiectasis by structural damage reversal or mortality
reduction are still aspirational goals, the reduction of exacerbations, symptoms control, improvement in
quality of life, preservation of lung function and treatment of the underlying disease may be feasible with
the current therapeutic means. Bronchiectasis remains a highly heterogeneous disease, and currently
available evidence supports the concept of multimodality treatment tackling each pathogenic pathway of
the “vicious vortex” [20].
An organised multimodality approach in A. O’Donnell’s view consists in the identification of a potentially
treatable underlying disease, the assessment of disease severity and an individualised treatment tailored to
patient’s needs, including airway clearance therapies, anti-inflammatory treatments, antibiotics and “N of
1” interventions.
Treatable causes of bronchiectasis include genetic disorders (e.g. cystic fibrosis, α1-antitrypsin deficiency
(AATD), primary ciliary dyskinesia (PCD)), immune defects (e.g. immunoglobulin deficiency, HIV
infection) and structural abnormalities (airway obstruction, aspiration)). A. O’Donnell stressed the
importance of identification and correct management of these underlying conditions.
Airway clearance therapy addresses to the airway structural dysfunction with the aim to overcome the
failure of mucus clearance. Active interventions include physical exercise (pulmonary rehabilitation),
mucus drainage techniques, the use of mechanical devices and pharmacological therapies [29, 30].
Hypertonic saline 7% improved lung function and quality of life in non-cystic fibrosis bronchiectasis
patients [31], bronchodilators and N-acetyl cysteine have an unknown efficacy, while mannitol and
rhDNase proved to be ineffective [32, 33].
Anti-inflammatory therapies include inhaled corticosteroids (ICS) and long-term use of macrolides. While
ICS should be used with caution after a judicious assessment of the risk/benefit ratio due to increased risk
of non-tuberculous mycobacterial infection [34], there is mounting evidence for the role of long-term
treatment with macrolides in exacerbation reduction [35]. Specific interventions like surgery [36], lung
transplantation [37] or anti-reflux procedure may be used in selected patients, on a case by case basis.
The management of chronic airway infection in bronchiectasis patients was reviewed by J. Chalmers from
the University of Dundee (UK) in the light of several recently published meta-analyses. Chronic airway
infection, particularly with P. aeruginosa, is associated with increased risk of hospitalisation and increased
mortality [38]. Current ERS guidelines for the management of adult bronchiectasis with⩾3 exacerbations
per year recommend long-term inhaled antibiotic for patients with P. aeruginosa infection and long-term
macrolide for non-P. aeruginosa infection [28].
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A recently published individual participant data meta-analysis of three randomised controlled trials of
macrolide antibiotics in adult patients with bronchiectasis conducted by CHALMERS et al. [35] demonstrated
that long-term macrolide antibiotics significantly reduced the frequency of exacerbations and prolonged
the time to first exacerbation, and was associated with improved quality of life as measured by the Saint
George’s Respiratory Questionnaire. Subgroup analyses revealed the highest level of benefit for patients
with a history of P. aeruginosa infection and one or two exacerbations per year.
The efficacy of inhaled antibiotics in the reduction of pulmonary exacerbations is supported by
inconsistent data from randomised clinical trials [39]. A systematic review and meta-analysis of 16
randomised controlled trials of inhaled antibiotic use in adult patients with bronchiectasis and chronic
respiratory tract infections showed a small but significant reduction in exacerbation frequency, without
significant improvement in quality of life [40]. In order to better identify the responders to inhaled
antibiotic therapy, SIBILA et al. [41] conducted two prospective studies of adults with bronchiectasis and a
post hoc analysis of a randomised trial of inhaled aztreonam. They found a significant improvement in
respiratory symptoms score (QOL-B-RSS) in favour of aztreonam compared with placebo in the subgroup
of patients with high bacterial load. This finding was further confirmed by a re-analysis of Orbit 3 and 4
studies conducted by CHALMERS et al. [42], showing significant improvements in respiratory symptoms
during the on-treatment periods which were lost during off-treatment periods. These newly accumulating
data may prompt an update of current guidelines for the management of bronchiectasis patients with
frequent exacerbations, as suggested by LASKA and CHALMERS [43] in a recent editorial.
J. Chalmers concluded the talk by briefly mentioning the promising data from the WILLOW study, which
demonstrated that reduction of neutrophil serine protease activity with brensocatib in patients with
bronchiectasis is associated with reduction in exacerbation risk and prolonged time to first exacerbation [44].
Thus, the future of bronchiectasis management may not be antibiotics.
F. Blasi (Milan, Italy) in the final talk of the session focussed on the concept of treatable traits in
bronchiectasis, emphasising that it could be a useful strategy to help clinicians consider the many different
aspects that must be addressed for the appropriate clinical management of patients with bronchiectasis [45].
F. Blasi further discussed two of the challenges frequently encountered by the physicians caring for
patients with bronchiectasis: identification of underlying diseases and understanding the inflammatory
pattern.
Despite using the current international guidelines suggested bundle of tests to investigate bronchiectasis
aetiology [46], the majority of patients are labelled as having “idiopathic bronchiectasis”. In order to
increase the chances to identify a treatable underlying etiology, FRANCESCHI et al. [47] proposed an
extensive bundle of tests, additionally including immunoglobulin (Ig)G subclasses, lymphocytes
subpopulations, HIV test, PICADAR score and nasal nitric oxide measurement for the screening of PCD,
sweat test and second level cystic fibrosis transmembrane conductance regulator genetic analysis, AATD
genetics and screening tests for connective tissue diseases. Using the extended bundle, the authors were
able to significantly increase the percentage of patients with a treatable aetiology and to identify the
presence of “subclinical” genetic alterations which could presumably find clinical expression by a
cumulative effect, after reaching a specific threshold.
Sputum neutrophil elastase is a marker of disease activity in bronchiectasis patients and associates with
increased risk of exacerbations, lung function decline and mortality [26]. The ability of a novel
semi-quantitative lateral flow device to provide a point of care assessment of neutrophil elastase activity
was tested by SHOEMARK et al. [48], who demonstrated a good correlation between high neutrophil elastase
activity as measured by the device and a significant increase in exacerbation frequency.
Another study conducted by SHOEMARK et al. [49] identified three inflammatory endotypes in patients with
clinically stable bronchiectasis: 1) neutrophilic inflammation; 2) eosinophilic and epithelial inflammation;
and 3) systemic inflammation, which may represent different “treatable traits”. Unpublished data from an
Italian cohort of 700 bronchiectasis patients bring additional evidence for the existence of a T2-high
endotype characterised by high levels of blood eosinophils, total IgE and oral nitric oxide. Finally, a group
of researchers from Hanover, Germany were able to demonstrate significant improvements in lung
function, quality of life and sputum production and a trend towards reduced exacerbation rate after
6 months of treatment with anti-IL5 (n=12) and anti-IL-5Rα (n=9) in 21 patients with clinically
significant bronchiectasis and features of refractory disease despite optimised therapy [50].
Airway infection: the microbiome and beyond
This poster session included ten studies providing novel insights on the airways’ microbiome and its
influence on the course of respiratory diseases.
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MESZAROS et al. [51] studied the incidence and economic burden of under-recognised respiratory infections
in older adults, such as pertussis. It was reported that the incidence of diagnosed pertussis in England
between 2009 and 2018 was higher among patients aged 50 years or more with comorbid asthma than in
patients 50 years or older without a history of asthma. It was also noted that given the under-diagnosis of
pertussis in adults further research is warranted on the potential health and economic impact of pertussis
in asthmatics.
In turn, VAN DEN STEEN et al. [52] assessed the seroprevalence of Bordetella pertussis in COPD patients
aged 40–85 years from the AERIS (Acute Exacerbations and Respiratory InfectionS in COPD) study in the
UK between 2009 and 2018. This study showed a seroprevalence of Pertussis spp. in more than 13% of
COPD patients which turned out to be higher than in the UK Clinical Practice Research Datalink and
indicated a substantial under-diagnosis of pertussis, warranting improved estimates and evaluation of its
impact on COPD outcomes.
MANN et al. [53] presented safety and disease outcomes from a novel respiratory syncytial virus (RSV)
challenge study in 60 to 75-year olds. RSV Memphis37b was administered intranasally to patients, and
then longitudinal disease profiles of older subjects were compared to a historical cohort of “younger”
healthy subjects. This novel RSV challenge of 60–75-year-olds was considered safe and induced an
appropriate level of disease, allowing for the assessment of vaccines and drugs targeted at 60–75-year-old
population.
VAN BRAECKEL et al. [54] presented preliminary clinical data from the international multicentre
collaboration aiming to improve chronic pulmonary aspergillosis (CPA) knowledge and patient care:
CPAnet registry. Data reflecting real-world clinical practice was collected from several international centres
and included CPA phenotype, comorbidities, treatment, outcomes and follow-up. Other CPA centres were
invited to join this initiative.
JABEEN et al. [55] compared performance of Illumina MiSeq, Nanopore sequencing, and RT-qPCR
(quantitative reverse transcription polymerase chain reaction) on total DNA extracts against culture/
MALDI-TOF for analysis of induced sputum samples from well-phenotyped severe asthma patients.
Haemophilus influenzae was identified as the dominant bacterial species by metagenomic sequencing using
MiSeq, Nanopore and was validated with H. influenzae plasmid-based RT-qPCR assay, allowing for
characterisation of this clinical phenotype.
KEIR et al. [56] presented the results of a microbiome analysis of the sputum from patients with stable
COPD and during exacerbations, performed by 16S rRNA (ribosomal ribonucleic acid) sequencing. There
were no statistically significant differences between stable and exacerbation microbiome profiles as a whole.
However, a subgroup analysis of bacterial exacerbations (with positive sputum culture) revealed an
association with significant loss of diversity and divergent changes in the overall composition of the
microbiome.
The next presentation was devoted to the prevalence and genetic adaptation of persistent P. aeruginosa
infections in patients with COPD. EKLÖF et al. [57] conducted whole-genome sequencing study of P.
aeruginosa strains sampled longitudinally from sputum cultures in 23 patients enrolled in a randomised
controlled trial in Denmark. The results indicated a relationship between P. aeruginosa infections and
genetically defined mucociliary clearance defects (GDMCD), as 37 P. aeruginosa genes were independently
mutated in two or more lineages, suggesting a positive selection for adaptive mutations which are also
important for the persistence of infection in patients with GDMCD.
The results of the largest multicentre evaluation of the COPD mycobiome were presented by TIEW et al. [58]
who examined COPD mycobiomes in 380 patients from Singapore, Malaysia and Scotland, based on
mortality and occurrence of serum specific-IgE against fungi. In patients with frequent exacerbations,
systemic specific-IgE responses against Aspergillus spp., Penicillium spp. and Curvularia spp., as well as
lower survival rates were noted, which, according to the authors, allows for COPD risk stratification based
on airway mycobiomes.
In connection with the widespread use of macrolides in the therapy of patients with frequent exacerbations
of chronic respiratory disease, NARAYANA et al. [59] studied airway microbiomes and corresponding
resistomes using deep sequencing metagenomic approaches from airway specimens of 85 individuals with
and without severe asthma, COPD and bronchiectasis. Macrolide resistance was found to be dominant in a
“core” airway resistome, but also a high prevalence of β-lactam, fluoroquinolone and tetracycline resistance
genes was reported. The greatest resistance was observed in COPD and bronchiectasis patients and was
found to be independent of disease status or prior antibiotic exposure. In addition, Streptococcus spp. and
Actinomyces spp. were revealed as potential microbial reservoirs of macrolide resistance including the
ermX, ermF and msrD genes.
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MU et al. [60] presented the results of a prospective evaluation of novel nanopore-based metagenomic
sequencing, which was used for rapid detection of bacterial pathogens in patients with lower respiratory
tract infections in comparison with those isolated by microbiology tests, then the discrepancies were
checked by real-time PCR. The sensitivity and specificity of the nanopore sequencing were 96.6% and
88.0%, respectively. Moreover, nanopore metagenomics identified pathogens in 63 out of 161
culture-negative samples, and 50 (79.4%) of them were verified. These results are promising for the
application of this new technique in the clinical practice, in order to achieve a more accurate diagnosis of
respiratory infections.
E-poster sessions: Tuberculosis and society, non-tuberculous mycobacteria and
latent tuberculosis infection, the young, the old and extrapulmonary tuberculosis,
multidrug-resistant tuberculosis
From the following session, we picked some of the most interesting posters presented on tuberculosis to
highlight the need for continued research in order to find better diagnostic and therapeutic tools for
tuberculosis in a pandemic year.
In one study, BUSSI et al. [61] used human induced-pluripotent stem cell derived macrophages (iPSDM)
together with high-content live-cell imaging, extracellular flux analysis and unbiased metabolomics to
investigate mitochondrial dynamics, Mycobacterium tuberculosis intracellular replication and
mitochondrial metabolism. Surprisingly, M. tuberculosis did not induce significant changes in the
mitochondrial area, length or width during the first 48 h of infection, however, the metabolic profile of
infected macrophages showed an increase in oxygen consumption and extracellular acidification rate after
48 h of infection. Conclusions stressed that macrophage metabolic reprogramming is required for the
control of M. tuberculosis replication and that, unlike other intracellular pathogens, changes in host cell
metabolism induced by M. tuberculosis might correlate with disruption of mitochondrial function rather
than morphology.
VLADIMIRSKY et al. [62] had an interesting presentation about a new M. tuberculosis culture format using
the lytic D29 mycobacteriophages for accelerated determination of drug sensitivity of M. tuberculosis to
first- and second-line anti-tuberculosis drugs in clinical isolates obtained after initial cultivation. When
comparing this new method with the Mycobacteria Growth Indicator Tube Bactec system in 108 clinical
isolates, the coincidence of results in determining drug sensitivity was demonstrated in up to 98% of cases.
In conclusion, using lytic mycobacteriophage to determine drug sensitivity for M. tuberculosis may be
rapid (up to 5 days), simple to implement and cost effective.
PANOVA et al. [63] studied an application of next-generation sequencing (NGS) to detect M. tuberculosis
resistance to first- and second-line anti-tuberculosis drugs aiming to find key drug resistance-associated
mutations of M. tuberculosis and compare it with phenotype-based methods. Drug resistance was
evaluated through single nucleotide polymorphisms identification in resistance-associated genes (rpsL,
rRNA, katG, inhA, rpoB, embB, pncA, rpsA, gyrA, gyrB, rrs, eis). NGS has been shown to be a highly
sensitive method for detecting mutations associated with resistance to isoniazid, rifampicin, ofloxacin,
levofloxacin, moxifloxacin (100%) and streptomycin (96.7%). Sensitivity values for detection of resistance
to ethambutol and kanamycin were lower (87.5% and 88.9%). Low sensitivity was observed for
pyrazinamide (29.4%), amikacin and capreomycin (60.0%). Specificity was more than 90% for all
anti-tuberculosis drugs.
SHARMA et al. [64] presented a six-case study on phenotyping and treatment of endobronchial tuberculosis
(EBTB) diagnosed on histopathology samples obtained via bronchoscopic (FOB) biopsy. EBTB was found
to mainly affect young females (<30 years), often involving left main bronchus. To prevent recurrent lobar
or complete lung collapse in spite of adequate tuberculosis treatment, the authors used balloon dilatation,
mucosal incisions and stents, but two patients required pneumonectomy in the end. Conclusion of the
author was that identification of this phenotype of tuberculosis and early application of bronchoscopy in
diagnosis and management of EBTB can prevent significant debilitation or lung tissue loss.
AL-SALIHI et al. [65] studied non-communicable (NCDs) comorbidities of tuberculosis in Iraq using data
from the national anti-tuberculosis drug resistance survey (DRS) finalised in 2015. Comorbid NCDs for
tuberculosis include diabetes, smoking, malnutrition and chronic lung disease. The data review of 1160
study participants revealed the following prevalence rates of NCDs: 33.8% were smokers, 17.6% had a
history of anaemia in the last 6 months, 24.4% had diabetes, 19.2% were underweight, 3.6% had asthma,
5.6% used steroid treatment on presentation and only 1.6% had severe chronic diseases (chronic
pulmonary disease/severe renal disease). The study evidenced that the first four conditions were related to
tuberculosis within 6 months prior to diagnosis.
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RUSAKOVA et al. [66] tried to identify predictors of death in patients with multi-drug resistant tuberculosis
(MDR-TB) and HIV in a retrospective cohort study with 1-year follow-up of 130 MDR-TB/HIV patients,
of whom, 31 (23.9%) patients had died. Several potential predictors of death were analysed: age, sex, body
mass index (BMI), history of previous treatment, adherence to treatment, CD4+ level in 1 µL, drug
resistance, liver size, haemoglobin and protein levels in g/L–1, hepatitis history, alcohol and drug addiction,
homelessness. Median values were calculated for the subgroups of patients who survived after one year of
follow-up (L) or who died within 1 year of follow-up (D). Statistically significant differences were obtained
for: homelessness (OR=4.8; p=0.05), alcohol and drug addiction (for alcoholism, OR=2.4; p=0.05; for drug
addiction, OR=2.8; p=0.02), history of being lost to follow-up (OR=4.7; p=0.05), BMI (L=29; D=19;
p=0.001), number of CD4+ (L=334; D=117; p=0.001), haemoglobin level (L=133; D=122; p=0.03) and the
total protein (L=77; D=22; p=0.006). Subsequent logistic regression analysis revealed that the most
important predictors of death for MDR-TB/HIV patients include history of being lost to follow-up, low
CD4+, and low BMI.
A very interesting method to treat tuberculosis patients was presented by HIDALGO et al. who studied
pulmonary surfactant as a new way to deliver anti-tuberculosis drugs. The interfacial properties and lipid
composition of pulmonary surfactant are ideal solutions to solubilise and transport hydrophobic drugs by
surfing the respiratory surface, targeting alveoli and phagocytic cells. The authors proposed to use
pulmonary surfactant to solubilise and transport the anti-tuberculosis drug, bedaquiline, over a respiratory
air–liquid interface and demonstrated that pulmonary surfactant can incorporate bedaquiline preserving
the interfacial performance as analysed in a Langmuir trough and a captive bubble surfactometer. Also,
they measured the appearance of the drug at the recipient trough by mass spectrometry (using a special in
vitro setup), and confirmed that pulmonary surfactant transports bedaquiline interfacially. The authors
observed a prominent antibiotic effect of pulmonary surfactant/bedaquiline formulations suggesting the
synergistic therapeutic effects of pulmonary surfactant/bedaquiline combinations compared with the drug
alone, and highlighted the potential of pulmonary surfactant as an anti-tuberculosis carrier [67].
Concluding remarks
In this comprehensive summary of several interesting sessions, the authors tried to share a glimpse of the
impressive amount of scientific information delivered at the ERS International Congress annually. We
encourage our readers to deepen their knowledge according to the field of interest by further reading of
the cited sources and we also hope that we have stimulated the desire for participation at future ERS
scientific events.
Author contributions: S. Frent reported on the session “The future of bronchiectasis management”; C. Calarasu reported
on the e-poster sessions “Tuberculosis and society”, “Non-tuberculous mycobacteria and latent tuberculosis infection”,
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K. Gashynova reported on the session “Airway infection: the microbiome and beyond”; and H. Keir reported on the
sessions “COVID-19 recapitulation”, “New developments in pandemic medicine: an update from the PREARE EU
research project” and “Post-COVID session”. All the authors reviewed and agreed on the content of the article.
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